Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 95%
filed 2026-07-27
Item 5.02
Nathan E. Tagg was appointed to the Board of Directors of Independent Bank Corporation, effective July 21, 2026, following the company's acquisition of HCB Financial Corp. on July 1, 2026. The Board was expanded from 10 to 11 members to accommodate his appointment, and he was also appointed to the Audit Committee. This is a clear executive appointment event, material to investors as it reflects post-acquisition board integration and governance changes.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-27
Item 5.03
Although Item 5.03 formally addresses bylaw amendments, the substantive disclosure centers on the appointment of Dave Crompton to the Board of Directors, announced in the press release (EX-99.1). The bylaw amendment itself is routine administrative housekeeping ("remove inapplicable and obsolete provisions"). The material event is Crompton's appointment, bringing four decades of leadership experience including 28 years at Cummins in senior executive roles, which would affect a reasonable investor's assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-27
Item 5.02
The Board elected Paul Diaz as a director effective July 28, 2026, to fill the vacancy created by Kenneth Burdick's resignation, and assigned him to the Audit Committee and Quality and Compliance Committee. Diaz brings substantial healthcare executive experience as former CEO of Myriad Genetics and Kindred Healthcare.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-07-27
Item 5.02
David Deno was appointed as President and Chief Executive Officer effective August 10, 2026, and concurrently appointed to the Board of Directors. The appointment follows a comprehensive succession planning process and includes a detailed employment agreement with a base salary of $1,000,000, bonus targets, equity awards, and severance provisions.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-27
The 6-K discloses the appointment of Alan Bash as Interim Chief Executive Officer effective July 24, 2026, following the resignation of Ying Huang. While both a departure and appointment occur, the principal disclosed action is Bash's appointment to the CEO role, with detailed background on his qualifications and prior experience. The appointment of an interim CEO to a critical executive position is material to investors assessing company leadership and continuity.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-27
Item 5.02
Five new trustees were elected to the Board effective July 21, 2026 (Robert F. Cummings, Jr., Lisa Hess, James G. Koman, David Lehman, and Robert Van Dore), increasing board size from one to six members, with James G. Koman designated as Board chairperson.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-27
Item 5.02
Nan (Richard) Hu was appointed as Chief Executive Officer, effective August 17, 2026, following a comprehensive board-led executive search conducted by Spencer Stuart. Xun (Kenneth) Li transitioned from Interim CEO to Chief Financial Officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-27
Item 5.02
Kymera Therapeutics appointed Terence Rooney, M.D., as Chief Medical Officer effective July 27, 2026, succeeding Jared Gollob who retired after eight years. Dr. Rooney will lead the company's clinical development strategy across its pipeline.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-27
Item 5.02
The Board appointed Ben Minicucci as a Class II director effective immediately on July 23, 2026. The disclosure centers on the appointment action itself, with detailed background on his qualifications as a public company CEO with transportation and operations expertise. While the filing also mentions a pre-existing partnership agreement with Alaska Air Group (where Minicucci serves as CEO), the principal disclosed event is the director appointment, not a related-party transaction or compensation arrangement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-27
Item 5.02
Brian Cox was appointed as a class III director of Ameresco, effective August 1, 2026, with a term expiring at the 2028 annual meeting. Cox brings over 20 years of data center energy infrastructure experience and will serve on the Audit and Nominating and Governance Committees.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-27
Item 5.02
The Board of Directors elected Dr. L. Thomas Richards as a director effective July 23, 2026, and appointed him to three board committees (Nominating and Corporate Governance, Finance and Capital Allocation, and Technology and Information Security). This is a clear executive appointment event. While the disclosure also includes compensation details, the principal action is the appointment of a new director to the board and committees, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-27
Item 5.02
The filing discloses the Board's appointment of Michael Lieb as the Company's principal accounting officer effective July 27, 2026. While the disclosure also includes compensatory arrangements (base salary of $385,000, 40% target bonus, and $1.2 million RSU award), the principal action is the appointment itself. The appointment of a principal accounting officer is a material governance event affecting the registrant's financial reporting structure and leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-24
Item 5.02
Celso L. Goncalves Jr. was appointed to the positions of President and Chief Financial Officer effective immediately on July 21, 2026, and simultaneously appointed to the Board. While the disclosure also includes compensatory adjustments (salary increase from $884,000 to $1,000,000 and enhanced severance terms), the principal disclosed action is the appointment to two significant executive roles and board membership, making this an exec_appointment event. The appointment of an internal executive to the President role alongside the CFO position is material to investors assessing company leadership.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-24
Item 5.02
The filing discloses two executive appointments: (1) Donavon P. Ternes appointed to the Boards of Directors of both the Corporation and Bank effective July 23, 2026, to fill vacancies from the death of Director William E. Thomas; and (2) Michael S. Van Stockum appointed as Senior Vice President and Chief Lending Officer of the Bank effective July 23, 2026. While a death of a director is also disclosed, the principal disclosed actions are the appointments themselves. The appointment of the CEO to the board and a new Chief Lending Officer are material governance and operational changes.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
The filing discloses the appointment of Neil Barua as an independent director of Carrier Global Corporation, effective July 24, 2026, with assignment to the Compensation Committee and Technology & Innovation Committee. This is a clear director appointment under Item 5.02(d), and the addition of a new board member with significant executive experience (current CEO of PTC Inc.) is material to investors' assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-24
Item 5.02
Ronald F. Stoops was appointed as Chief Financial Officer, effective October 1, 2026, succeeding James C. Kerr. The filing emphasizes Stoops' qualifications and readiness to assume the CFO position as part of the company's succession plan.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 7.01
Mr. David Haddock has been appointed as Executive Vice President, General Counsel and Secretary of Pediatrix Medical Group, Inc., assuming the senior leadership role vacated by Ms. Moore's departure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-24
Item 5.02
Alexander Fink was elevated to principal executive officer with expanded responsibilities including HR, finance, and operations, effective immediately with direct Board reporting. The filing also discloses concurrent promotions of Garrett Kasper to Chief Communications Officer and a strategic role shift for Serhii Kupriienko to lead the newly created Swarmer Labs innovation division.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
Lauren Selig was appointed as a director of Renatus Tactical Acquisition Corp I effective July 21, 2026, and simultaneously appointed to the Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee. The filing discloses her extensive background in entertainment, technology, AI, blockchain, and venture investment, along with her current board service at XPRIZE and Pendrell Corporation. This is a clear executive appointment event material to investors assessing the company's governance and board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
The filing discloses the appointment of Irina Krasik to TransDigm's Board of Directors, effective immediately on July 22, 2026. The principal action is a person taking a board role, with detailed background on her qualifications in M&A, investing, and corporate governance. Board appointments are material governance events affecting the composition and oversight of the company.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-24
EX-99.1
The announcement discloses the appointment of Juan Carlos Hurtado Parra as Acting President effective July 31, 2026, following the departure of Ricardo Roa Barragán. While the primary action is a person taking a role (appointment), the context involves both an executive departure and a succession event. The appointment of an acting president to lead a major integrated energy company with over 19,000 employees is material to investors assessing leadership continuity and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-24
The 6-K discloses the Board of Directors' approval of William Vella Nozaki's election as Chief Energy Transition and Sustainability Officer (DTEN) on an interim basis, effective August 1, 2026. This is a material executive appointment to a C-suite officer role at a major energy company, affecting investor assessment of leadership and strategic direction in energy transition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-24
Item 1.01
On July 20, 2026, the Company entered into a consulting agreement with W4 LLC to formalize the engagement of Alex Odagiu as Interim President, a role to which he was appointed by the Board on June 23, 2026. Mr. Odagiu will serve 32 hours per week at $25,000 monthly compensation, reporting directly to the Board pending appointment of a permanent CEO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-24
Item 5.02
On July 22, 2026, the Board appointed William B. Miller, the Company's Chief Financial Officer, to serve as Interim Principal Executive Officer, following David Namdar's departure as CEO. This appointment addresses interim leadership of the registrant's principal executive function.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
The filing discloses the appointment of Alan Khalili as Chief Financial Officer effective July 27, 2026, under Item 5.02. The principal disclosed action is a person taking a role—a named executive officer appointment. While the employment agreement includes compensation details (base salary of $450,000, 50% discretionary bonus, 50,000 RSUs, and severance provisions), the core event is the appointment itself, not the compensation arrangement. This is material to investors as CFO appointments affect financial leadership and strategy execution.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-24
The filing discloses two principal events under Item 5.02: the resignation of director Yuji Ishida (effective immediately on July 23, 2026) and the appointment of Kevin Cheong Jia Jin to the Board on July 24, 2026, including appointment to the Compensation Committee. While both a departure and appointment occurred, the filing's primary focus and the most material forward-looking disclosure centers on the appointment of the new director and his compensation terms ($10,000 annual retainer), making exec_appointment the most salient classification. The filing also discloses termination of four material service agreements (RyuShin Advisors, PeakValue LLC, Cherish Gloss Group, and Jipsy Trade Limited), but these are secondary to the board composition change.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-24
The filing discloses the appointment of Anuj Goel as Chief Financial Officer effective August 24, 2026, with detailed compensation terms including a base salary of AUD$650,000 (~USD$455,000), short-term incentive eligibility up to 100% of base salary, long-term incentive eligibility up to 200% of base salary, and a sign-on grant of restricted stock units valued at AUD$1,352,000 (~USD$946,400). While the filing also discloses Timothy Broadfoot's resignation as CFO, the principal disclosed action centers on the appointment of a new CFO with material compensation arrangements, making exec_appointment the most salient classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
The filing discloses the appointment of Kewei Huang as Co-Chief Executive Officer on July 22, 2026, under Item 5.02. The Board determined that appointing an additional executive leader alongside the existing CEO would enhance executive oversight and drive innovation. This is a clear executive appointment of a named officer to a senior leadership role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
The filing discloses the appointment of Mikkel Pitzner, age 58, to the Board of Directors of Brownie's Marine Group, Inc., effective July 16, 2026. The principal disclosed action is a person taking a board role, with specified compensation of $4,500 per quarter in common stock. This is a clear director appointment under Item 5.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
The filing discloses the appointment of Michael H. Carrel to the Board of Directors of Inspire Medical Systems, effective immediately on July 20, 2026, along with his assignment to two Board committees. While the disclosure includes compensatory arrangements (annual cash retainers and equity awards), the principal disclosed action is the appointment of a new director with significant healthcare and medical device industry experience, making this an exec_appointment event. The material nature is evident from the detailed biographical information and the immediate effectiveness of the appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
David I. Goulden, former CFO of Booking Holdings with 35+ years of management and financial leadership experience, was appointed to HPE's Board of Directors effective July 24, 2026, and assigned to the Finance and Investment Committee and HR and Compensation Committee.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
Thomas E. Waldron was appointed as a director of Kontoor Brands, effective immediately, increasing the Board from six to seven directors. Waldron brings deep expertise from his prior role as EVP and Chief Operating Officer of Kontoor.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-24
Item 5.02
Robert Sharp was elected to serve as a director of the Company effective July 23, 2026, in connection with the closing of the debt exchange transaction, pursuant to the Preferred Shareholders' designation rights under the Certificate of Designation for Series A Cumulative Convertible Preferred Stock.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-24
The 6-K discloses the appointment of Mr. Chan Ka Ki as Chief Financial Officer of Bluemount Holdings Ltd., effective July 24, 2026, to fill the vacancy created by Ms. Lui Tung Mui's resignation. While both a departure and an appointment occur, the principal disclosed action is the appointment of a named executive to a C-suite officer role, which is material to investors assessing the company's financial leadership and governance. The biographical information and confirmation of no related-party conflicts support this as a formal executive appointment disclosure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-07-24
Item 5.02
The filing discloses both the resignation of Eugene N. Padgett as Chief Accounting Officer and the appointment of Janice Zwinggi to assume that role in addition to her CFO position. While both events occur, the principal disclosed action centers on the appointment of Zwinggi to the Chief Accounting Officer role, making exec_appointment the most salient classification. The appointment of a named executive to a principal accounting officer position is material to investors assessing the registrant's financial reporting oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-23
Item 5.02
The filing discloses the appointment of Kevin J. Hagen as Principal Accounting Officer and Vice President and Global Controller on July 23, 2026. While the section also mentions Patrick J. Dawson's departure from the same role, the principal disclosed action centers on the appointment of a new Principal Accounting Officer—a key financial reporting position. The appointment of a new Principal Accounting Officer is material to investors as it affects the registrant's financial reporting oversight and governance structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
Albemarle Corporation appointed Eduardo De Salles Bartolomeo as an independent director, effective July 21, 2026. Bartolomeo brings 30+ years of experience in mining and logistics, including service as CEO of Vale S.A. from 2019 to 2024, and will receive an annual retainer of $120,000 and a restricted stock grant of $170,000.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
The filing discloses the appointment of Michael T. Keegan to Pioneer Bancorp's Board of Directors on July 21, 2026. The principal action is a person taking a role—specifically, a board directorship at a publicly traded financial institution. Mr. Keegan brings four decades of banking executive experience, including 31 years at M&T Bank as Senior Executive Vice President and Head of Community Banking, and will serve on the Audit and Compensation Committees. This is a material governance event affecting the composition and expertise of the board.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-07-23
The 6-K discloses four new appointments to Santander UK's Executive Committee: Tom Ranger as CFO (effective 1 October 2026), Steve Affleck as Chief Accounting Officer (immediate effect), Michael Christodoulides as Chief Compliance Officer (effective 1 November 2026), and Iñaki Perkins as Head of Cards & Payments. These are material executive appointments at a major financial institution, with the CFO role being particularly significant. The filing also notes Angel Santodomingo's departure as CFO effective 31 October 2026, but the principal disclosed action is the appointment of his successor and three other senior executives.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
Victor Dzau, M.D., was appointed to the Board of Directors of United Therapeutics on July 22, 2026, increasing the Board size to 13 members. As part of his appointment, Dr. Dzau received initial equity compensation consisting of 380 RSUs and 1,190 stock options, plus pro-rata awards.
View raw filing on EDGAR →
RH
(RH)
8-K
Exec appointment
confidence 92%
filed 2026-07-23
Item 7.01
The Item 7.01 disclosure announces two executive leadership changes: the promotion of Sandy Pilon to Chief Customer Experience & Values Officer and the appointment of Ryan G. Hassanein as Chief Legal & Compliance Officer. While both events are disclosed, the appointment of Hassanein as a new Chief Legal & Compliance Officer joining the Executive Leadership Team from outside the company represents the more significant material event. Executive appointments to C-suite roles are material to investors assessing management quality and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-07-23
Item 5.02
Seven directors (Aaron Elliott, Ann Costello, Peter Kolchinsky, Carole Nuechterlein, Deepika Pakianathan, Randal Scott, and Douglas VanOort) and four executive officers (Aaron Elliott as CEO, Linh H. Le as CFO, Riley Ennis as Chief Product Officer, and Cheng-Ho Jimmy Lin as Chief Scientific Officer) were appointed to the New Freenome Board and management team immediately following the merger effective time.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
Michael J. Maddox was appointed as a Board Member and Director of CVB Financial Corp. effective July 22, 2026, with concurrent appointment to the Bank's board and multiple board committees. While the disclosure also includes compensatory arrangements (annual director fee of $77,000 and pro-rated restricted stock grant), the principal disclosed action is the appointment of a named executive to a director role. The appointment of an experienced banking executive with 20+ years of experience and prior CEO roles is material to investors assessing board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 7.01
Jorge J. García was appointed President and Chief Executive Officer effective September 1, 2026, succeeding retiring CEO Javier D. Ferrer. Concurrently, Lidio V. Soriano was appointed Executive Vice President and Chief Financial Officer, and Luis F. Sousa was appointed Executive Vice President and Chief Risk Officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
Jeffrey Rowe was appointed as Executive Vice President and Chief Operating Officer of ADM, effective August 17, 2026, in a newly created role overseeing commercial businesses, global manufacturing, and R&D. Rowe brings 30+ years of industry experience, including prior service as CEO of Syngenta Group, and will report directly to the CEO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
ImageneBio appointed Yanina Grant-Huerta as Chief Financial Officer, principal financial officer, and principal accounting officer effective July 20, 2026, with a base salary of $450,000, 40% bonus eligibility, RSU and option grants, and severance benefits.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-23
Item 5.02
The filing discloses both a director resignation (Adam Malinowski) and an appointment (Gregory Williams to the Board effective July 23, 2026). While both events occur, the principal disclosed action centers on the appointment of Williams to fill the vacancy, with detailed background on his qualifications, experience, and compensation terms. The appointment of a new director to the board is material to investors' assessment of governance and board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-23
Item 5.02
Nicolas Calcoen, a senior Amundi executive (Deputy CEO, Head of Strategy, Finance and Control), was appointed as a Class III director of Victory Capital Holdings effective July 23, 2026, replacing Dominique Carrel-Billiard who resigned the same date due to his departure from Amundi. The appointment was recommended by the Nominating Committee and is presented as a strategic addition to the Board.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-07-23
Item 8.01
The disclosure centers on the Board-approved appointment of William Clement as Chief Commercial Officer effective August 1, 2026, a senior executive role reporting to the CEO with responsibility for commercial strategy and the independent agent network. While the filing also mentions transitions for Jim Applegate and Matthew Dannegger, Clement's appointment is the primary announced action and the most material event—a new C-suite officer joining the Executive Leadership Team at a major transportation company. The appointment would affect investor assessment of leadership and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-07-23
Item 5.02
The filing discloses the appointment of Eric Seidel as a director of FreeCast, Inc., effective immediately on July 17, 2026. The Board unanimously approved both the increase in board size from three to four directors and Seidel's appointment to the Board and as the second member of the Audit Committee. This is a clear executive appointment event, material to investors as it affects board composition and governance structure, particularly given the company's Nasdaq listing compliance requirements.
View raw filing on EDGAR →